Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Chief Medical Officer | January 06, 2021 | January 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date January 06, 2021 · Filed January 08, 2021
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2021 Filed Jan 8, 2021 17:24 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000904454-21-000020 · edgar.xml · derivative · entry 2 Neumann Frank · CIK 0001837786 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-01-06 F2 · derivative.exercise_date: The stock option vests as to 25% of the shares subject to the option on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 17:24 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000020 · edgar.xml · nonDerivative · entry 1 Neumann Frank · CIK 0001837786 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's inducement award program. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the shares subject to the award on the first anniversary of the date of grant and as to an additional 6.25% of the shares at the end of each successive three month period following the first anniversary of the date of grant until the 4th anniversary of the date of grant (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.